Solid Neoplasm
FDA Approves Tecelra, the First Engineered Cell Therapy for Solid Tumors, to Treat Synovial Sarcoma
Tecelra, Adaptimmune, FDA approval, engineered cell therapy, solid tumor, synovial sarcoma, MAGE-A4 antigen, TCR cell therapy
Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal
Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition
Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###
Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib
BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront
BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany
Endeavor’s $132.5 Million Funding Accelerates Fibrotic Lung and Solid Tumor Therapeutic Development
Endeavor, funding, fibrotic lung, solid tumors, therapeutic development, medical research, healthcare innovation.
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating